Scientists have assembled a “timeline” of the unseen progress of Alzheimer’s before symptoms appear.A team at Washington University School of Medicine looked at families with a genetic risk of the disease.Writing in the New England Journal of Medicine, they say signs appeared up to 25 years before t

This is a guest post by Moriah Pollock-Hawthorne, Haverford University.I was an intern at NICE International and an American university student with aspirations to become a doctor. In an effort to learn about universal health coverage and experience a single-payer healthcare system in action, I came

โรคติดเชื้อ Human Papillomavirus (HPV) เป็นโรคติดต่อทางเพศสัมพันธ์ที่พบได้บ่อยและสามารถแพร่กระจายได้ง่ายเพียงการสัมผัสทางผิวหนัง (skin-to-skin contact

Highlights Economic evidence (cost-effectiveness information) can be used to inform policy-making process in supporting the movement towards universal health coverage. Published literature has focused on methods to set a cost-effectiveness threshold (CET) which can be used to guide the cost-eff

(Reuters) – Republican governors bent on rejecting the healthcare law’s expanded insurance coverage for millions of low-income Americans may see their gambit backfire if their party fails to sweep the November elections.Five governors have vowed to opt out of the Medicaid expansion for low-income pe

The study suggests that the price of patented medicine in Thailand should be controlled based on equity pricing and outcome pricing. Equity pricing can be estimated from the international reference price and outcome pricing can be evaluated from therapeutic referencing or the pharmacoeconomic price. Moreover, in a case study of 7 medicines granted

Abstract Background and Objectives The Health Intervention and Technology Assessment Program was commissioned to conduct a cost–utility and budget impact analysis of enzyme replacement therapy (ERT) for Gaucher disease types 1 and 3b. The findings from this assessment are to support the decision-m

Abstract Background and Objectives The Health Intervention and Technology Assessment Program was commissioned to conduct a cost–utility and budget impact analysis of enzyme replacement therapy (ERT) for Gaucher disease types 1 and 3b. The findings from this assessment are to support the decision-m

(Reuters) – AstraZeneca is to conduct a new global clinical trial of key new heart drug Brilinta involving 11,500 patients with peripheral artery disease, Britain’s second biggest drugmaker said on Tuesday.Peripheral artery disease affects around 27 million people in Europe and North America, with s